Back to Search Start Over

Two distinct receptor-binding domains of human glycyl-tRNA synthetase 1 displayed on extracellular vesicles activate M1 polarization and phagocytic bridging of macrophages to cancer cells.

Authors :
Park MC
Goughnour PC
Jun S
Cho S
Song E
Kim SB
Kim HY
Hyun JK
Kim P
Jung HS
Kim S
Source :
Cancer letters [Cancer Lett] 2022 Jul 28; Vol. 539, pp. 215698. Date of Electronic Publication: 2022 May 09.
Publication Year :
2022

Abstract

Macrophages play important roles in cancer microenvironment. Human cytosolic glycyl-tRNA synthetase (GARS1) was previously shown to be secreted via extracellular vesicles (EVs) from macrophages to trigger cancer cell death. However, the effects of GARS1-containing EVs (GARS1-EVs) on macrophages as well as on cancer cells and the working mechanisms of GARS1 in cancer microenvironment are not yet understood. Here we show that GARS1-EVs induce M1 polarization and facilitate phagocytosis of macrophages. GARS1-EVs triggers M1 polarization of macrophage via the specific interaction of the extracellular cadherin subdomains 1-4 of the cadherin EGF LAG seven-pass G-type receptor 2 (CELSR2) with the N-terminal WHEP domain containing peptide region of GARS1, and activates the RAF-MEK-ERK pathway for M1 type cytokine production and phagocytosis. Besides, GARS1 interacted with cadherin 6 (CDH6) of cancer cells via its C-terminal tRNA-binding domain to induce cancer cell death. In vivo model, GARS1-EVs showed potent suppressive activity against tumor initiation via M1 type macrophages. GARS1 displayed on macrophage-secreted extracellular vesicles suppressed tumor growth in dual mode, namely through pro-apoptotic effect on cancer cells and M1 polarization effect on macrophages. Collectively, these results elucidate the unique tumor suppressive activity and mechanism of GARS1-EVs by activating M1 macrophage via CELSR2 as well as by direct killing of cancer cells via CDH6.<br /> (Copyright © 2022. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1872-7980
Volume :
539
Database :
MEDLINE
Journal :
Cancer letters
Publication Type :
Academic Journal
Accession number :
35523311
Full Text :
https://doi.org/10.1016/j.canlet.2022.215698